Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 8590697)

  • 1. VAPEC-B chemotherapy in the treatment of aggressive non-Hodgkin's lymphoma: a retrospective analysis of 45 patients.
    Singer JM; Mijovic A; Pettingale KW; Nethersell A; Dobbs HJ; Samaratunga IR; Lakhani A; Mufti GJ
    Clin Oncol (R Coll Radiol); 1995; 7(6):366-70. PubMed ID: 8590697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pilot study on the use of the ProMACE-CytaBOM regimen as a first-line treatment of advanced follicular non-Hodgkin's lymphoma. Gruppo Italiano per lo Studio dei Linfomi.
    Baldini L; Guffanti A; Gobbi P; Colombi M; Federico M; Avanzini P; Cavanna L; Pieresca C; Silingardi V; Maiolo AT
    Cancer; 1997 Mar; 79(6):1234-40. PubMed ID: 9070503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicentre combined chemotherapy protocol for large cell advanced non Hodgkin's lymphoma.
    Dumont J; Charpy-Validire P; Mosseri V; Gabarre J; Belanger C; Turpin F; Binet JL; Dreyfus F; Fourquet A; Janvier M
    Hematol Oncol; 1991; 9(4-5):197-207. PubMed ID: 1720759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomised comparison of CHOEP versus alternating hCHOP/IVEP for high-grade non-Hodgkin's lymphomas: treatment results and prognostic factor analysis in a multi-centre trial.
    Köppler H; Pflüger KH; Eschenbach I; Pfab R; Birkmann J; Zeller W; Holle R; Steinhauer UE; Gropp C; Oehl S
    Ann Oncol; 1994 Jan; 5(1):49-55. PubMed ID: 8172793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Weekly VAPEC-B chemotherapy for high grade non-Hodgkin's lymphoma: results of treatment in 184 patients.
    Radford JA; Whelan JS; Rohatiner AZ; Deakin D; Harris M; Stansfeld AG; Swindell R; Wilkinson PM; James RD; Lister TA
    Ann Oncol; 1994 Feb; 5(2):147-51. PubMed ID: 7514433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective, non-randomised phase 1-2 trial of VACOP-B with filgrastim support for HIV-related non-Hodgkin's lymphoma.
    Sawka CA; Shepherd FA; Franssen E; Brandwein J; Dotten DA; Routy JP; Walker IR; St-Louis J; Taylor M; Arts K; Crump M; Foote M
    Biotechnol Annu Rev; 2005; 11():381-9. PubMed ID: 16216784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
    Wunderlich A; Kloess M; Reiser M; Rudolph C; Truemper L; Bittner S; Schmalenberg H; Schmits R; Pfreundschuh M; Loeffler M;
    Ann Oncol; 2003 Jun; 14(6):881-93. PubMed ID: 12796026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CHOP with high dose cyclophosphamide consolidation versus CHOP alone as initial therapy for advanced stage, indolent non-Hodgkin's lymphomas.
    Pan D; Qin J; Farber C; O'Brien J; Filippa D; Portlock CS
    Leuk Lymphoma; 2003 Jun; 44(6):967-71. PubMed ID: 12854895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Preliminary outcome for patients with relapsed or resistant advanced non-Hodgkin's lymphoma treated by EPOCH regimen].
    Huang HQ; Jiang WQ; Wang W; Zhou ZM; Xia ZJ; Lin XB; Li YH; Xu RH; Zhang L; Xu GC; Sun XF; Liu DG; He YJ; Guan ZZ
    Ai Zheng; 2003 Apr; 22(4):389-92. PubMed ID: 12703995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitoxantrone, etoposide, cytarabine and prednisone as salvage therapy for refractory non-Hodgkin lymphoma (NHL) and alternated with CHOP in previously untreated patients with NHL.
    Merk K; Ideström K; Johansson B; Kimby E; Lindemalm C; Osby E; Björkholm M
    Eur J Haematol; 1991 Jan; 46(1):33-7. PubMed ID: 1988304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase III trial of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) versus cisplatin, etoposide, bleomycin and prednisone (CisEBP) for the treatment of advanced non-Hodgkin's lymphoma of high grade malignancy. The Danish Lymphoma Study Group.
    Andersen J; Thorling K; Bentzen SM; Brincker H; Christensen BE; Pedersen M
    Acta Oncol; 1990; 29(8):995-9. PubMed ID: 1703769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-line treatment with brief-duration chemotherapy plus rituximab in elderly patients with intermediate-grade non-Hodgkin's lymphoma: phase II trial.
    Hainsworth JD; Litchy S; Lamb MR; Rodriguez GI; Scroggin C; Greco FA
    Clin Lymphoma; 2003 Jun; 4(1):36-42. PubMed ID: 12837153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Male fertility after VAPEC-B chemotherapy for Hodgkin's disease and non-Hodgkin's lymphoma.
    Radford JA; Clark S; Crowther D; Shalet SM
    Br J Cancer; 1994 Feb; 69(2):379-81. PubMed ID: 7507693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility of high-dose chemotherapy without stem cell support as a first-line treatment for non-Hodgkin's aggressive lymphoma: a pilot study.
    Inoue R; Natazuka T; Shimoyama M; Tamekane A; Kajimoto Y; Iwata N; Matsuoka H; Chihara K; Matsui T
    Leuk Lymphoma; 2000 Jan; 36(3-4):315-21. PubMed ID: 10674903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy with MECOP-B for intermediate-grade and high-grade non-Hodgkin's lymphoma in Saudi Arabia: clinical results and analysis of prognostic factors.
    Ibrahim EM; Bunyan RF; al-Mulhim FA; al-Nabhan AA; Ibrahim RE
    Acta Haematol; 1996; 96(3):126-34. PubMed ID: 8876608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensive weekly combination chemotherapy for patients with intermediate-grade and high-grade non-Hodgkin's lymphoma.
    Sweetenham JW; Mead GM; Whitehouse JM
    J Clin Oncol; 1991 Dec; 9(12):2202-9. PubMed ID: 1720454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MACOP-B chemotherapy for the treatment of high grade and intermediate grade non Hodgkin's lymphoma.
    Oster W; Forsthuber T; Hennekeuser HH; Gamm H; Lindemann A; Schmitz G; Fuhr HG; Hinterberger R; Kreiter H; Thoenes W
    Blut; 1990 Jan; 60(1):23-7. PubMed ID: 1688725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A brief-duration combination chemotherapy for elderly patients with poor-prognosis non-Hodgkin's lymphoma.
    McMaster ML; Johnson DH; Greer JP; Wolff SN; Hildreth CR; Greco FA; Hainsworth JD
    Cancer; 1991 Mar; 67(6):1487-92. PubMed ID: 1705861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of optimal treatment on elderly patients with aggressive non-Hodgkin's lymphoma: more patients treated with unaffected response rates.
    Peters FP; Fickers MM; Erdkamp FL; Wals J; Wils JA; Schouten HC
    Ann Hematol; 2001 Jul; 80(7):406-10. PubMed ID: 11529466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The MACOP-B and VACOP-B combination chemotherapy for young patients with intermediate-grade non-Hodgkin's lymphoma.
    Dreiher J; Shpilberg O; Raanani P; Chetrit A; Ben-Bassat I
    Leuk Res; 1998 Nov; 22(11):997-1002. PubMed ID: 9783801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.